252 related articles for article (PubMed ID: 2075470)
1. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
2. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
4. Improvement of anaemia with desferrioxamine in haemodialysis patients.
Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
[TBL] [Abstract][Full Text] [Related]
5. Hypochromic anaemia in chronic renal failure--role of aluminium.
Varma PP; Kumar R; Prasher PK; Roy ND
J Assoc Physicians India; 1999 Jul; 47(7):690-3. PubMed ID: 10778588
[TBL] [Abstract][Full Text] [Related]
6. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
[TBL] [Abstract][Full Text] [Related]
7. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
[TBL] [Abstract][Full Text] [Related]
8. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
Vogelsang U
Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
[TBL] [Abstract][Full Text] [Related]
9. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
[TBL] [Abstract][Full Text] [Related]
10. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
12. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
13. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
[TBL] [Abstract][Full Text] [Related]
14. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
Short AI; Winney RJ; Robson JS
Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
[TBL] [Abstract][Full Text] [Related]
15. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
Abreo K; Brown ST; Sella M; Trapp G
J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
[TBL] [Abstract][Full Text] [Related]
16. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
17. [Aluminum in chronic renal failure].
Głuszek J; Adamczak H
Rocz Panstw Zakl Hig; 1993; 44(1):43-8. PubMed ID: 8235341
[TBL] [Abstract][Full Text] [Related]
18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
19. Serum ferritin and tissue iron in anemic dialysis patients.
Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
[TBL] [Abstract][Full Text] [Related]
20. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Seifert A; von Herrath D; Schaefer K
Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
